Company intelligence / Profile preview

Vybion

California, United Statesvybion.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Vybion’s lead candidate, INT41, is an AAV-delivered single-chain variable fragment (scFv) intrabody targeting the toxic N-terminal fragment of mutant huntingtin protein. In animal models of Huntington’s disease, INT41 reduced toxic protein accumulation and gene dysregulation and stabilized or improved motor and cognitive function. The company has received FDA Orphan Drug Designation for this program but has not yet entered clinical trials as of the latest available information.

Therapeutic areas: Neurology
Modalities: Intrabodies (scFv fragments)Gene therapy (AAV vectorized delivery)
Industry: Biotech

Drug pipeline

1 asset

INT41

Preclinical

Partnerships

CHDI Foundation (strategic agreement for animal studies leading to IND-enabling work)Past collaboration with Caltech on ProCode technology development

Beyond the preview

Go deeper on Vybion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vybion.

Explore the full profile